强化早期业务布局！博腾股份增聘尹云星为公司副总经理

2026年8月22日，重庆博腾制药科技股份有限公司（以下简称“公司”）宣布增聘尹云星先生为公司高级管理人员，出任副总经理，全面负责公司小分子新药研发中心管理工作。

尹云星先生在制药行业有二十余年工作经历，在快速合成、发现工艺化学和早期工艺研发领域拥有丰富的经验以及团队组建和管理能力。加入公司前，尹云星先生曾就职于上海药明康德新药开发有限公司、天津药明康德新药开发有限公司等，历任助理研究、主任、副总裁等职务。

公司董事长、总经理居年丰表示：“欢迎尹云星先生加入公司高管团队。尹云星先生在早期项目交付、体系管理、客户拓展、团队管理等领域均有成熟的经验积累，高度契合公司现阶段战略发展需求，期待他在公司平台上赋能公司早期业务发展，夯实早期研发管线大盘，为公司业务长期可持续发展注入新动能。

尹云星表示：“非常荣幸加入博腾大家庭。我期待在未来与团队一起，围绕公司整体战略，聚焦小分子新药研发中心核心工作，立足快速合成、发现工艺化学、早期工艺研发等核心领域，持续优化研发流程、搭建专业化研发团队、完善早期研发体系，高效推进新药早期技术攻关与项目孵化，持续提升公司小分子新药研发项目交付效率与创新能力，助力公司打造差异化技术优势，推动更多优质创新成果落地。”

Porton Appoints Yunxing Yin as Corporate Vice President to Strengthen Small-Molecule R&D Leadership

August 22, 2026 — Porton Pharma Solutions Ltd. (Porton) announced the appointment of Mr. Yunxing Yin to its senior management team as Corporate Vice President. In this role, he will oversee the strategic and operational management of the Small?Molecule R&D Platform of Porton.

With more than 20 years of specialized experience in the pharmaceutical industry, Yunxing possesses extensive expertise in rapid synthesis, discovery process chemistry and early-phase process development, alongside proven capabilities in team building and operational management. Prior to joining Porton, Yunxing held successive roles including Research Associate, Director and Vice President at WuXi AppTec.

Oliver Ju, Chairman and Chief Executive Officer of Porton commented, “We are delighted to welcome Yunxing to our senior leadership team. Yunxing’s robust expertise in early?phase project delivery, R&D system optimization, customer development and team management aligns with Porton’s strategic growth roadmap. We look forward to his contributions in empowering our early?phase business growth, solidifying our early?phase pipeline, and fueling sustainable long?term innovation for the company.”

“I am greatly honored to join Porton,” said Yunxing. “I look forward to partnering closely with our teams to advance Porton’s core strategic goals centered on the Small-Molecule R&D Platform. Building on our competencies in rapid synthesis, discovery process chemistry, and early-phase process development, we will streamline R&D workflows, scale up specialized technical teams, and strengthen our end-to-end early-phase R&D system. My priority is to fast-track technical breakthroughs and early-phase project incubation, elevate the overall delivery efficiency and innovative capability of our small-molecule DS projects, build distinct technological differentiation, and drive the successful translation and commercialization of high-quality innovations.”

END

博腾股份成立于2005年，为全球药企、生物科技公司及科研机构等提供从临床前研究到药品上市全生命周期的端到端CDMO服务，涵盖小分子药物、多肽与寡核苷酸药物、蛋白与偶联药物以及细胞与基因治疗药物的原料药到制剂全流程。截至2025年末，公司拥有全球员工4300余人，累计服务客户1400余家，成功交付项目超5000个。我们始终坚持以客户为中心，致力于提供创新可靠的全球化CDMO解决方案，让好药更早惠及大众。

Founded in 2005, Porton Pharma Solutions provides end-to-end CDMO services from pre-clinical to commercial stages. Our capabilities span Small Molecules, TIDES, Biologics and Conjugates (ADCs, AOCs, DACs, PDCs, RDCs, etc.), and Advanced Therapy Medicinal Products, from drug substance to drug product. As of 2025, Porton has over 4,300 employees globally, served more than 1,400 customers, and delivered over 5,000 projects. We are committed to a customer-centric approach, delivering innovative and reliable global CDMO solutions, enabling earlier access to good medicines.